Construction of prophylactic human papillomavirus type 16 L1 capsid protein vaccine delivered by live attenuated Shigella flexneri strain sh42

Acta Biochimica et Biophysica Sinica

Volumn 37, Issue 11, 2005, Pages 743-750

  Yang, Xiao Feng ^a,c   Qu, Xin Zhong ^c   Wang, Kai ^a   Zheng, Jin ^a   Si, Lü Sheng ^a   Dong, Xiao Ping ^b   Wang, Yi Li ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Attenuated Shigella flexneri; Cervical cancer; Human papillomavirus type 16; Prophylactic; Vaccine

Indexed keywords

ANIMALIA; CAVIA PORCELLUS; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; MIRIDAE; MURINAE; PROKARYOTA; SHIGELLA; SHIGELLA FLEXNERI;

BACTERIAL VACCINE; CAPSID PROTEIN; LIVE VACCINE;

ANIMAL; ARTICLE; DRUG DELIVERY SYSTEM; GENE THERAPY; GENETICS; GUINEA PIG; HELA CELL; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOLOGY; METABOLISM; METHODOLOGY; PROTEIN ENGINEERING; SHIGELLA FLEXNERI; VIRUS INFECTION;

ANIMALS; BACTERIAL VACCINES; CAPSID PROTEINS; DRUG DELIVERY SYSTEMS; GENE THERAPY; GUINEA PIGS; HELA CELLS; HUMAN PAPILLOMAVIRUS 16; HUMANS; PAPILLOMAVIRUS INFECTIONS; PROTEIN ENGINEERING; SHIGELLA FLEXNERI; VACCINES, ATTENUATED;

EID: 33644794232     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1111/j.1745-7270.2005.00109.x     Document Type: Article

References (20)

1. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavims and cervical cancer. J Clin Pathol 2002, 55: 244-265
2. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001, 37: S4-S66
3. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 LI and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991, 185: 251-257
4. Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ, Mast. TC et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 LI virus-like particle vaccine. J Natl Cancer Inst 2001, 93: 284-292
5. Nardelli-Haefliger D, Wirthner D, Schiller JT, Lowy DR, Hildesheim A, Ponci F, de Grandi P. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst 2003, 95: 1128-1137
6. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM et al. A controlled trial of a human papillomavirus type 16 vaccine. J Natl Cancer Inst 2002, 347: 1645-1651
7. Baud D, Benyacoub J, Revaz V, Kok M, Ponci F, Bobst M, Curtiss R 3rd et al. Immunogenicity against human papillomavirus type 16 virus-like particles is strongly enhanced by the PhoP' phenotype in Salmonella enterica serovar Typhimurium. Infect Immun 2004, 72: 750-756
8. Hartman AB, Powell CJ, Schultz CL, Oaks EV, Eckels KH. Small-animal model to measure efficacy and immunogenicity of Shigella vaccine strains. Infect Immun 1991, 59: 4075-4083
9. Elsinghorst EA. Measurement of invasion by gentamicin resistance. Methods Enzymol 1994, 236: 405-420
10. Sansonetti PJ, Arondel J, Fontaine A, d'Hauteville H, Bemardini ML. OmpB (osmo-regulation) and icsA (cell-to-cell spread) mutants of Shigella flexneri: Vaccine candidates and probes to study the pathogenesis of shigellosis. Vaccine 1991, 9: 416-422
11. Zheng J, Ma J, Yang XF, Liu HL, Cheng HW, Si LS, Wang YL. Highly efficient and economical baculovirus expression system for preparing human papillomavirus type 16 virus-like particles. Acta Biochim Biophys Sin 2004, 36: 548-552
12. Hartman AB, Van de Verg LL, Collins HH Jr, Tang DB, Bendiuk NO, Taylor DN, Powell CJ. Local immune response and protection in the guinea pig keratoconjunctivitis model following immunization with Shigella vaccines. Infect Immun 1994, 62: 412-420
13. Czerkinsky CC, Nilsson LA. Nygren H, Ouchterlony O, Tarkowski A. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J Immunol Methods 1983, 65: 109-121
14. Roden RB, Hubbert ML, Kirnbauer R, Breitburd F, Lowy DR, Schiller JT. Papillomavirus LI capsids agglutinate mouse erythrocytes through a proteinaceous receptor. J Virol 1995, 69: 5147-5151
15. Zheng J, Si L, Song J, Sun X, Yu J, Wang Y. Enhanced immune response to DNA-based HPV16 L1 vaccination by costimulatory molecule B7-2. Antiviral Res 2003, 59: 61-65
16. Benyacoub J, Hopkins S. Potts A, Kelly S, Kraehenbuhl JP, Curtiss R 3rd, de Grandi P et al. The nature of the attenuation of Salmonella typhimurium .strains expressing human papillomavirus type 16 virus-like particles determines the systemic and mucosal antibody responses in nasally immunized mice. Infect Immun 1999, 67: 3674-3679
17. Sizemore DR, Branstrom AA, Sadoff JC. Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization. Science 1995, 270: 299-302
18. Blumberg RS, Lencer WI, Zhu X, Kim HS, Claypool S, Balk SP, Saubermann LJ et al. Antigen presentation by intestinal epithelial cells. Immunol Lett 1999, 69: 7-11
19. Shata MT, Stevceva L, Agwale S, Lewis GK, Hone DM. Recent advances with recombinant bacterial vaccine vectors. Mol Med Today 2000, 6: 66-71
20. Breitburd F, Kirnbauer R, Hubbert NL, Nonnenmacher B, Trin-Dinh-Desmarquet C, Orth G, Schiller JT et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995, 69: 3959-3963